×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
CLL
Katie Kosko
Patients with chronic lymphocytic leukemia should learn about the latest advancements, says one expert.
Kristie L. Kahl
The addition of Venclexta to Gazyva induced prolonged progression-free survival – or the time from treatment to disease worsening – among patients with previously untreated chronic lymphocytic leukemia.
Katie Kosko
Patients with chronic lymphocytic leukemia have newer options that include targeted therapy combinations and CAR-T cell therapy.
OncLive Staff
The Food and Drug Administration has approved the combination use of Venclexta plus Gazyva for the frontline treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Beth Fand Incollingo
Christopher Harington Dwyer, founder of CLL Canada and online chat contributor, leaves a legacy of support and knowledge.
Kristie L. Kahl
The Bruton tyrosine kinase inhibitor showed a statistically-significant and clinically-meaningful improvement in progression-free survival in patients with previously-treated CLL.
Lynn Aspey
Most people have heard the term "new normal" for individuals living, surviving and struggling with cancer. What actually does that mean?
Kristie L. Kahl
Risk for disease progression among patients with chronic lymphocytic leukemia over time differed between those with mutated or unmutated disease, showing that gene somatic hypermutation plays a role throughout the disease course.
Kristie L. Kahl
An expert discusses new treatment options for patients diagnosed with CLL.
Kristie L. Kahl
Patients with relapsed or refractory chronic lymphocytic leukemia may have more options now than ever before, according to William G. Wierda, M.D., Ph.D.